| 13.06 17:02 | dpa-AFX: *JOHNSON & JOHNSON REPORTS INITIAL PHASE 1B DATA FOR DUAL-TARGETING CAR-T THERAPY JNJ-4496 IN R/R LARGE B-CELL LYMPHOMA |
| 12.06 17:02 | dpa-AFX: *J&J REPORTS PROMISING EARLY TRIAL RESULTS FOR LEUKEMIA DRUG COMBO TARGETING AML WITH GENE MUTATIONS |
| 11.06 14:31 | dpa-AFX: Johnson & Johnson: TREMFYA Significantly Reduces Symptoms Of PsA In APEX Study |
| 11.06 14:07 | dpa-AFX: *JOHNSON & JOHNSON'S TREMFYA SHOWS SIGNIFICANT IMPROVEMENT IN PSORIATIC ARTHRITIS IN PHASE 3B APEX STUDY |
| 03.06 19:27 | dpa-AFX: Johnson & Johnson's DARZALEX FASPRO Improves Myeloma Survival And MRD Response Rates |
| 03.06 18:53 | dpa-AFX: Johnson & Johnson Says Carvykti Achieved Treatment-free Remissions For 5 Years In Myeloma Patients |
| 03.06 17:06 | dpa-AFX: Johnson & Johnson's Trispecific Antibody Show Promising Response In Myeloma Patients |
| 03.06 16:59 | dpa-AFX: *JOHNSON & JOHNSON'S DARZALEX FASPRO QUADRUPLET ACHIEVES DEEP MRD RESPONSE, ENHANCES PFS IN NDMM |
| 03.06 16:57 | dpa-AFX: *J&J : CARVYKTI SINGLE INFUSION DELIVERS 5-YEAR TREATMENT-FREE REMISSIONS IN R/R MULTIPLE MYELOMA |
| 03.06 16:56 | dpa-AFX: *J&J'S TRISPECIFIC ANTIBODY SHOWS PROMISING EARLY RESPONSE IN HEAVILY PRETREATED MULTIPLE MYELOMA PATIENTS |
| 03.06 14:52 | dpa-AFX: Johnson & Johnson Reports Positive Results From Phase 3 AMPLITUDE Study In Prostate Cancer |
| 03.06 14:05 | dpa-AFX: *JOHNSON & JOHNSON ANNOUNCES PROMISING PHASE 3 RESULTS FOR NIRAPARIB COMBO IN METASTATIC PROSTATE CANCER |
| 28.05 14:04 | dpa-AFX: Johnson & Johnson To Present At Bernstein's Strategic Decisions Conference; Webcast At 9:00 AM ET |
| 23.05 15:13 | dpa-AFX: Medical Experts Urge FDA To Adopt New Policies To Prohibit Talc Use In Consumer Products |
| 23.05 14:04 | dpa-AFX: *FDA EXPERTS URGE BAN ON TALC IN CONSUMER PRODUCTS, CITING HEALTH CONCERNS |
| 21.05 04:03 | dpa-AFX: FDA Panel Votes In Favor Of J&J' DARZALEX FASPRO For High-Risk Smoldering Multiple Myeloma Treatment |
| 09.05 17:20 | dpa-AFX: JNJ's Icotrokinra Shows Positive Phase 3 Results In Scalp, Genital Psoriasis |
| 09.05 14:08 | dpa-AFX: *JOHNSON & JOHNSON'S ICOTROKINRA SHOWS SIGNIFICANT SKIN CLEARANCE IN PHASE 3 PSORIASIS STUDY |
| 05.05 15:33 | dpa-AFX: Johnson & Johnson Reports Positive Phase 3 ASTRO Study Data For TREMFYA In Ulcerative Colitis |
| 05.05 14:50 | dpa-AFX: J&J Reports Positive Data From Long-term Extension Study Of TREMFYA In Ulcerative Colitis |
|
|
